Henry A. Nasrallah
Department of Psychiatry and Behavioral Neuroscience
University of Cincimati
260 Stetson Street
Suite 3200
USA
Name/email consistency: high
- Clinical pharmacology of paliperidone palmitate a parenteral long-acting formulation for the treatment of schizophrenia. Gilday, E., Nasrallah, H.A. Rev. Recent. Clin. Trials (2012)
- A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia. Nasrallah, H.A., Gopal, S., Gassmann-Mayer, C., Quiroz, J.A., Lim, P., Eerdekens, M., Yuen, E., Hough, D. Neuropsychopharmacology (2010)
- Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Nasrallah, H.A. Mol. Psychiatry (2008)
- Reliability, validity and ability to detect change of the Personal and Social Performance scale in patients with stable schizophrenia. Nasrallah, H., Morosini, P., Gagnon, D.D. Psychiatry. Res (2008)
- The roles of efficacy, safety, and tolerability in antipsychotic effectiveness: practical implications of the CATIE schizophrenia trial. Nasrallah, H.A. J. Clin. Psychiatry (2007)
- Introduction: evaluating the evidence: Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and beyond. Nasrallah, H.A. J. Clin. Psychiatry (2007)
- The case for long-acting antipsychotic agents in the post-CATIE era. Nasrallah, H.A. Acta. Psychiatr. Scand (2007)
- Carbamazepine and valproate for the treatment of bipolar disorder: a review of the literature. Nasrallah, H.A., Ketter, T.A., Kalali, A.H. J. Affect. Disord (2006)
- Metabolic findings from the CATIE trial and their relation to tolerability. Nasrallah, H.A. CNS. Spectr (2006)
- Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania. Nasrallah, H.A., Brecher, M., Paulsson, B. Bipolar. Disord (2006)
- Improving patient outcomes in schizophrenia: achieving remission. Nasrallah, H.A., Lasser, R. J. Psychopharmacol. (Oxford) (2006)
- Defining and measuring clinical effectiveness in the treatment of schizophrenia. Nasrallah, H.A., Targum, S.D., Tandon, R., McCombs, J.S., Ross, R. Psychiatr. Serv (2005)
- An overview of common medical comorbidities in patients with schizophrenia. Nasrallah, H.A. J. Clin. Psychiatry (2005)
- Neurologic comorbidities in schizophrenia. Nasrallah, H.A. J. Clin. Psychiatry (2005)
- Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone. Nasrallah, H.A., Duchesne, I., Mehnert, A., Janagap, C., Eerdekens, M. J. Clin. Psychiatry (2004)
- Lower mortality in geriatric patients receiving risperidone and olanzapine versus haloperidol: preliminary analysis of retrospective data. Nasrallah, H.A., White, T., Nasrallah, A.T. Am. J. Geriatr. Psychiatry (2004)
- Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care. Nasrallah, H.A., Newcomer, J.W. J. Clin. Psychopharmacol (2004)